Literature DB >> 3665703

Contrast sensitivity and pattern visual evoked potential in patients with glaucoma.

H Abe1, S Hasegawa, K Iwata.   

Abstract

Contrast sensitivity and pattern visual evoked potential (VEP) were measured in cases of ocular hypertension and primary open-angle glaucoma at various stages. The visual field of each eye was examined quantitatively and the retinal nerve fiber layer and optic disc were precisely assessed with magnified stereoscope fundus photography. This study revealed that contrast sensitivity of the eyes with glaucoma was within the normal range in the very early stage of the disease. As optic nerve damage advanced, high- or low-frequency loss developed. Further optic nerve damage produced a level type of loss. Pattern VEPs also showed increasing abnormalities as glaucomatous optic nerve damage progressed. Measurements of contrast sensitivity and pattern VEP were found not to be as sensitive as quantified precise visual field measurement or color stereoscopic fundus photography for detection of minor optic nerve damage in cases of early glaucoma. These methods may be useful, however, as an objective and subjective monitor of progression of optic nerve damage in glaucoma.

Entities:  

Mesh:

Year:  1987        PMID: 3665703     DOI: 10.1007/bf00162721

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  8 in total

1.  Specific deficits of flicker sensitivity in glaucoma and ocular hypertension.

Authors:  C W Tyler
Journal:  Invest Ophthalmol Vis Sci       Date:  1981-02       Impact factor: 4.799

2.  Acquired color vision changes in glaucoma. Use of 100-hue test and Pickford anomaloscope as predictors of glaucomatous field change.

Authors:  S M Drance; R Lakowski; M Schulzer; G R Douglas
Journal:  Arch Ophthalmol       Date:  1981-05

3.  [The selective impairment of the three color mechanisms (red-, green-, and blue-sensitive mechanisms) isolated by the new color campimeter in pathological eyes with fundus disease. 1st. Report: Studies of static threshold campimetry in normal subjects].

Authors:  H Abe; T Sakai
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1982

4.  The effects of visual field changes and ocular hypertension on the visual evoked potential.

Authors:  G Bartl
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

5.  A simple grating test for contrast sensitivity: preliminary results indicate value in screening for glaucoma.

Authors:  G B Arden; J J Jacobson
Journal:  Invest Ophthalmol Vis Sci       Date:  1978-01       Impact factor: 4.799

6.  Pattern-reversal electroretinograms in unilateral glaucoma.

Authors:  P Wanger; H E Persson
Journal:  Invest Ophthalmol Vis Sci       Date:  1983-06       Impact factor: 4.799

7.  Vision through cataracts.

Authors:  R Hess; G Woo
Journal:  Invest Ophthalmol Vis Sci       Date:  1978-05       Impact factor: 4.799

8.  Interocular comparison of contrast sensitivities in glaucoma patients and suspects.

Authors:  A Atkin; M Wolkstein; I Bodis-Wollner; M Anders; B Kels; S M Podos
Journal:  Br J Ophthalmol       Date:  1980-11       Impact factor: 4.638

  8 in total
  4 in total

1.  The visual evoked potential in acute primary angle closure glaucoma.

Authors:  K W Mitchell; C M Wood; J W Howe; W H Church; G T Smith; S R Spencer
Journal:  Br J Ophthalmol       Date:  1989-06       Impact factor: 4.638

2.  Mid-peripheral pattern electrical retinal responses in normals, glaucoma suspects, and glaucoma patients.

Authors:  N H Shorstein; W W Dawson; M B Sherwood
Journal:  Br J Ophthalmol       Date:  1999-01       Impact factor: 4.638

3.  PRBS-determined temporal frequency characteristics of VEP in glaucoma.

Authors:  Keiko Momose; Motohiro Kiyosawa; Nobuyuki Nemoto; Hiroshi Mori; Manabu Mochizuki; Joseph Jy-Haw Yu
Journal:  Doc Ophthalmol       Date:  2004-01       Impact factor: 2.379

Review 4.  Clinical characteristics and current treatment of glaucoma.

Authors:  Laura P Cohen; Louis R Pasquale
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-02       Impact factor: 6.915

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.